Clinical Trial Update: GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study [NA]

View source ↗

Summary

The REDUCE Post Approval Study is evaluating antiplatelet strategies to reduce recurrent stroke in patients with patent foramen ovale treated with the GORE CARD…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Patent Foramen Ovale
• Stroke

Drugs mentioned

• GORE CARDIOFORM Septal Occluder

Snippet

Sponsor: W.L.Gore & Associates | Conditions: Stroke, PFO - Patent Foramen Ovale | NA | Status: RECRUITING